Shares of Kintara Therapeutics, Inc. (KTRA) are rallying more than 22% after the company received Fast Track Designation from the FDA for REM-001 for the treatment of patients with cutaneous metastatic breast cancer (CMBC).
REM-001 was studied in four Phase 2/3 trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy.
"We believe this designation is a key component of our future clinical and regulatory strategy as we continue to seek funding, in particular grants, to restart REM-001 clinical development as soon as possible," said Robert E. Hoffman, President and CEO of Kintara.
KTRA is at $4.52 currently. It has traded in the range of $3.50-$42.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.